Remedy Meds charges no membership fee; medication, unlimited provider visits, phone support, and shipping are bundled into a single monthly price shown after intake. Only the microdose plan price ($189/month) is publicly documented.

Remedy Meds offers month-to-month GLP-1 plans with no prepaid or multi-month commitment options. This comparison examines what that means for cost planning and explores alternatives with prepaid savings.

Remedy Meds offers tiered GLP-1 pricing—microdose at $189/month, standard plans higher—but does not publish whether cost changes when your provider increases dose. We walk through what the evidence shows, where it stops, and how PlexusDx's flat-rate policy compares.

Remedy Meds charges $189/month for microdose semaglutide and $299/month for standard-dose, both month-to-month with no membership fee. Prices appear only after intake completion.

Remedy Meds shows pricing only after intake, with a microdose plan captured at $189/month and standard-dose figures reported separately. We compare verified costs, inclusions, and transparency against PlexusDx's published rates.

Switching GLP-1 providers without missing a dose requires coordination. We compare Remedy Meds and PlexusDx pricing, timing mechanics, and prescription transfer steps so you can plan a seamless transition.

Remedy Meds is a legitimate telehealth provider offering compounded GLP-1 medications with a 4.7-star Trustpilot rating. Its verified microdose plan costs $189/month, higher than some competitors, and standard-dose pricing is not published publicly.

MEDVi advertises a first-month rate then raises to ongoing refill pricing for compounded semaglutide; Remedy shows no prices up front. Which structure delivers lower 12-month costs?

Remedy Meds publishes no product prices until after intake, but verified evidence shows $189/month microdose and $299–$399/month standard-dose figures. We compare those rates against PlexusDx's published ladder.

PlexusDx charges $129/month for microdose GLP-1; Remedy Meds charges $189/month for the same tier. We compare verified pricing, transparency, and care bundles head-to-head.

Peak Wellness publishes standard rates and prepaid totals for injectable semaglutide and tirzepatide; Remedy Meds showed one microdose rate through its intake quiz. We normalize the evidence, calculate 12-month costs, and show where PlexusDx fits.

Remedy Meds offers a verified microdose plan at $189/month all-in with unlimited clinician visits. Zealthy advertises standard-dose medication from $199/month plus a required $135/month membership. We compare structures, verify what's confirmed, and show where PlexusDx fits.

Fridays bundles coaching and unlimited visits at $249–$359/month, Remedy guarantees results at $189/month microdose-only, and PlexusDx publishes $129–$289/month rates across five formats. Evidence-based cost and support comparison.

Embody publishes standard-dose prices upfront at $299–$349/month. Remedy Meds shows microdose pricing ($189/month) only after intake. PlexusDx lists both tiers with committed-term options: $129/month for microdose and $189/month for semaglutide injection, month-to-month.

Eden sells standard-dose injections with a results pledge; Remedy Meds sells microdose GLP-1 with unlimited visits. Neither structure dominates every priority—this comparison maps what each program includes, what it costs, and where PlexusDx fits the same decisions.

MEDVi, Remedy Meds, and PlexusDx all dispense compounded semaglutide and tirzepatide — but the annualized cost, billing cadence, and clinical-oversight model differ in ways the landing pages don't show. This guide walks the real numbers, the September 2025 FDA warning-letter context, and where PlexusDx Weight Management Protocols ($129/mo to $349/mo) plus the Precision Peptide Genetic Test fit relative to both.

Last reviewed: May 12, 2026 Last updated: May 12, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations....